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Available online 5 March 2013AbstractA 34-year-old man presented feeling generally unwell with dark urine 3 days after inhaling amyl nitrite. His initial heart rate was 118/min,
blood pressure 130/85 mmHg, O2 saturation 85% on 15 L/min oxygen, and Glasgow coma score 15. He was pale, with clear chest sounds on
auscultation. His hemoglobin was 60 g/L, bilirubin 112 mM, and methemoglobin concentration 6.9% on an arterial blood gas. Amyl nitrite-
induced hemolysis and methemoglobinemia were diagnosed. Methylene blue was not administered because of the relatively low methemo-
globin concentration and the possibility of inducing further hemolysis. He was subsequently confirmed as having glucose-6-phosphate dehy-
drogenase deficiency, which had originally been diagnosed in childhood. Amyl nitrite toxicity may include concurrent methemoglobinemia and
hemolysis. Administration of methylene blue for clinically significant methemoglobinemia can induce further hemolysis.
Copyright  2013, Taiwan Society of Emergency Medicine. Published by Elsevier Taiwan LLC. All rights reserved.
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Amyl nitrite is one of a number of alkyl nitrites otherwise
known as “poppers”, “rush”, or “liquid gold” when utilized
recreationally. Amyl nitrite produces smooth muscle relaxa-
tion leading to dizziness, euphoria, a feeling of warmth and
changes in sphincter tone. This combination of effects en-
hances sexual experiences in some individuals.
There have been reports of hemolysis due to oxidative
stress secondary to amyl nitrite.1 In patients who have glucose-
6-phospate dehydrogenase (G6PD) deficiency, optimizing
effective oxygen delivery in the face of amyl nitrite-induced
methemoglobinemia and hemolysis can be challenging.2. Case report
A 34-year-old man of Greek ethnicity presented to the
emergency department (ED) via his primary physician with* Corresponding author. Victorian Poisons Information Centre, Austin
Hospital, Heidelberg 3084, Victoria, Australia.
E-mail address: Anselm.Wong@austin.org.au (A. Wong).
2211-5587/$ - see front matter Copyright  2013, Taiwan Society of Emergency
http://dx.doi.org/10.1016/j.jacme.2012.12.005dark urine for 3 days following his return from Vanuatu 4
weeks earlier. He had drunk 100 half-coconut shells of kava
while there. He also complained of diarrhea, abdominal pain,
and headaches. Four days prior to presentation he had inhaled
amyl nitrite. There was no other toxic exposure, change in
habit and diet or drug use. He had become increasingly
dyspneic and noticed dark urine. He had a history of blood
transfusions after ingesting fava beans when he was aged 2
years but could not remember his condition. On arrival in the
ED he was afebrile, and had a Glasgow coma score of 15,
blood pressure of 130/83 mmHg, respiratory rate of 18/min,
heart rate of 118/min, and oxygen saturation of 81% on room
air and 85% on 15 L/min oxygen. He was pale, with clear
chest sounds, and a soft, nontender abdomen.
He had a hemoglobin (Hb) of 60 g/L [reference range (rr)
130e180 g/L], white cell count 38.2 g/L (rr 4e11 g/L) and
platelets of 408  109/L (rr 150e400  109/L). A blood smear
showed marked macrocytic anemia with bite cells, blister
cells, spherocytes, polychromasia, left shift neutrophilia, and
an appearance consistent with oxidative hemolysis. No ma-
larial parasites were seen on thick or thin blood smears. His
bilirubin was 112 mM (rr < 18 mM), haptoglobin 0.2 g/LMedicine. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Main pathway of methemoglobin (MetHb) reduction. Methylene blue
reduces MetHb to hemoglobin (Hb). This requires nicotinamide adenine
dinucleotide phosphate hydrogen (NADPH).
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98e192 IU/L). The rest of his liver function tests were within
normal limits. The infectious diseases service considered an
infectious cause unlikely. Given the time course, his symptoms
and signs did not fit those of kava toxicity. Blood gas analysis
also confirmed methemoglobinemia with a peak methemo-
globin (MetHb) concentration of 6.9%.
Amyl nitrite toxicity leading to methemoglobinemia and
hemolysis on a background of G6PD deficiency (given the
previous reaction to fava beans) was suspected. The G6PD
deficiency was later confirmed by no demonstrable activity on
assay and a review of his childhood records. The patient’s
methemoglobinemia, which may have been higher prior to
presentation, was not severe enough to warrant treatment with
methylene blue during his time in the ED or during hospital-
ization. There was also concern about the potential adverse
effects of methylene blue in the context of concurrent hemo-
lysis and G6PD deficiency. He was admitted for observation
and supportive care, and received three units of red blood
cells. His oxygenation improved, hemoglobin levels remained
stable post-transfusion, and MetHb levels decreased back to
normal; he was discharged after 3 days.
3. Discussion
There have been reports of hemolysis due to oxidative
stress secondary to amyl nitrite and in patients with G6PD
deficiency.1e4 Bogart et al described methemoglobinemia and
hemolysis secondary to nitrite administration in a non-G6PD
deficient individual.5 However, documented cases of
measured methemoglobinemia and hemolysis occurring
concurrently following amyl nitrite exposure in G6PD defi-
ciency are rare. This raises some interesting management is-
sues, specifically in regard to the traditional use of methylene
blue for methemoglobinemia, which could be harmful.
Maintenance of an adequate concentration of reduced
glutathione enables erythrocytes to withstand a degree of
oxidative stress. Glutathione reduces oxidants and maintains
sulfhydryl groups that protect the integrity of the cell mem-
brane.6 G6PD catalyzes the first step in the pentose-phosphate
pathway of glycolysis. This pathway leads to the production of
reduced glutathione and requires nicotinamide adenine dinu-
cleotide phosphate hydrogen (NADPH). Volatile nitrite-
induced hemolysis can occur without G6PD deficiency, but
is more likely in patients with the condition because of
decreased glutathione concentrations.
MetHb is a form of Hb that has been oxidized from the
Fe2þ (ferrous) to Fe3þ (ferric) state. This form of Hb cannot
carry oxygen. The MetHb concentration is normally main-
tained through reduction mechanisms at less than 1%. Meth-
ylene blue is the antidote for the treatment of significant amyl
nitrite-induced methemoglobinemia. It is reduced to leuko-
methylene blue by MetHb reductase, reducing MetHb to Hb.
This reaction (Fig. 1) requires the presence of NADPH.7
Successful treatment of methemoglobinemia with methy-
lene blue requires adequate NADPH. Patients with G6PD
deficiency have low endogenous NADPH. In addition, ourpatient had hemolytic anemia and required additional NADPH
to produce reduced glutathionine to combat amyl nitrite-
induced oxidative stress. Administration of methylene blue
in this case could have theoretically worsened the hemolytic
anemia through two mechanisms: competitive loss of NADPH
required to produce reduced glutathione because of utilization
of NADPH for reduction of methylene blue; and methylene
blue itself acting as a mild oxidative stressor.
Methylene blue is generally indicated for treatment of
MetHb concentrations >30%, or in symptomatic patients
regardless of the MetHb concentration. Anemic patients are
also less likely to tolerate significantly raised MetHb con-
centrations. Methylene blue in high doses (>7 mg/kg) can
cause paradoxical methemoglobinemia secondary to a direct
oxidative effect on Hb. Common side effects of methylene
blue include headache, dizziness, nausea, vomiting, dyspnea,
and chest discomfort.8 In our patient, the measured MetHb
concentration was relatively low and, despite significant ane-
mia, it was decided not to administer antidotal treatment.
Instead packed red blood cells were transfused with good ef-
fect, but not without a risk of a transfusion reaction. Admin-
istration of methylene blue to patients with G6PD deficiency
has been relatively contraindicated, but remains controversial.
Over 400 million people worldwide are thought to be deficient
in G6PD and it is likely that many who were unaware of their
G6PD status have been given methylene blue. Despite this,
there are relatively few reports of related adverse effects. In
addition, patients with G6PD deficiency have varying con-
centrations of the enzyme. Some authors suggest cautious
administration of methylene blue to patients with symptomatic
MetHb and G6PD deficiency.9 In cases of severe acquired
25A. Wong et al. / Journal of Acute Medicine 3 (2013) 23e25methemoglobinemia where methylene blue has failed, ex-
change transfusions or hyperbaric oxygen may be beneficial.10
Appropriate treatment needs to be discussed with toxicologists
and hematologists on a case by case basis. Chronic kava
toxicity was considered early in the ED course of this patient.
The roots of the kava plant are used to produce a drink with
sedative and anesthetic properties that is consumed throughout
the Pacific islands. Chronic toxicity effects include dermop-
athy, ataxia, hair loss, and liver enzyme derangement (elevated
gamma-glutamyl transferase and alkaline phosphatase), with
most symptoms reversible on discontinuation of use. There
have been reports of hepatic failure associated with kava
extract.11 These symptoms did not correlate with our patient’s
presentation. Patients with acute toxicity may present with
vomiting, sweating, dizziness, dilated pupils, blepharospasm,
urinary retention, muscle weakness, acute dystonic reactions,
transient liver enzyme elevation, and decreased consciousness
and motor reflexes.
4. Conclusion
This case highlights the interplay between amyl nitrite, a
drug that induces hemolysis and methemoglobinemia, and
potential management considerations in a patient with G6PD
deficiency. This is a rare occurrence, but serves to remind
treating physicians of the many issues related to management
of each condition and the patient as a whole.Conflicts of interest
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